RYTHMOL
LOE ApproachingNDAORALTABLET
Approved
Nov 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYTHMOL (propafenone) is an oral small-molecule antiarrhythmic agent approved in 1989 for the treatment of cardiac arrhythmias. It works as a Class IC antiarrhythmic by blocking sodium channels and slowing conduction velocity in cardiac tissue. The drug is used to maintain normal heart rhythm in patients with atrial fibrillation and other supraventricular arrhythmias.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30%), indicating a mature brand requiring lifecycle management rather than growth-focused resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
Started Apr 2012
38 enrolled
Arrhythmia, Cardiac
Career Relevance
Working on RYTHMOL offers experience in mature product management, market access strategy, and lifecycle extension within a competitive therapeutic area. Roles emphasize commercial optimization, payer negotiations, and sustaining market share in the face of generic/biosimilar competition rather than launch or growth acceleration.
Brand Manager
Worked on RYTHMOL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.